BOWELTREAT AS
Boweltreat.no - Sliter du på IBS? Prøv pulveret TRP.,Boweltreat.no - Pulver utviklet for mennesker med fordøyelseplager
Boweltreat.no selger vi pulver som er utviklet for mennesker som sliter med fordøyelsesplager og lidelser, for eksempel irritabel tarm (IBS).,MAGO™ er utviklet av Norges fremste tarmspesialist og professor i indremedisin, prof. em. Arnold Berstad. Han mener at en tarmflora i ubalanse i større grad kan normaliseres over tid med hensiktsmessig diett enn det andre behandlingstilbud får til. MAGO™ består rett og slett av en blanding av flere naturstoffer
Keywords
researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors
Links
Organization
- CEO
- TL
- Chairman of the board
- TL
- Years since formation
- 9 years
- since Dec 7, 2016
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 500
- 1 share class
- Total number of shareholders
- 1
- person
Financials
- Total operating income 2023
- 251,608
- NOK
- Annual total result 2023
- -220,275
- NOK
- Total equity 2023
- 772,166
- NOK
Last update: Aug 29, 2024
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
TL | Managing Director/CEO | 100 % directly |
Board
| Name | Role | Shares |
|---|---|---|
TL | Chairman | 100 % directly |
Others
| Name | Role | Shares |
|---|---|---|
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
TL | Managing Director/CEO, Chairman | 100 % directly |
Last update: Apr 13, 2023
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
TL | Ordinary shares | 500 | 100 % |
Last update: May 24, 2024
Financials
in NOK
Summary
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 251,608 | 452,107 | 885,759 |
Annual Total Result | -220,275 | -177,250 | 72,698 |
Total assets | 868,839 | 1,196,708 | 1,524,241 |
Total liabilities | 96,672 | 154,274 | 304,557 |
Total equity | 772,166 | 1,042,434 | 1,219,684 |
P&L
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 251,608 | 452,107 | 885,759 |
Total operating costs | 472,119 | 664,631 | 761,808 |
Operating result | -220,511 | -212,524 | 123,951 |
Financial income/costs | 236 | -14,720 | -30,749 |
Profit before tax | -220,275 | -227,244 | 93,202 |
Total tax & extraordinary income/cost | 0 | -49,994 | 20,504 |
Annual Total Result | -220,275 | -177,250 | 72,698 |
Balance overview
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total fixed assets | 262,276 | 424,548 | 555,210 |
Total current assets | 606,562 | 772,160 | 969,031 |
Total assets | 868,839 | 1,196,708 | 1,524,241 |
Short term debt | 79,925 | 154,274 | 287,810 |
Long term debt | 16,747 | 0 | 16,747 |
Total liabilities | 96,672 | 154,274 | 304,557 |
Contributed capital | 500,000 | 500,000 | 500,000 |
Retained earnings | 272,166 | 542,434 | 719,684 |
Total equity | 772,166 | 1,042,434 | 1,219,684 |
Total equity and liabilities | 868,839 | 1,196,708 | 1,524,241 |
Classification
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology